SAGE THERAPEUTICS CLINICAL RESEARCH
Clinical Research Study in Mild Cognitive Impairment associated with Parkinson’s Disease (PD-MCI)
The PRECEDENT study is evaluating an investigational treatment for cognitive deficits such as memory and attention in Parkinson’s. This phase 2 study is sponsored by Sage Therapeutics, Inc. and is recruiting people aged 50 to 75 years who are diagnosed with mild cognitive impairment related to idiopathic Parkinson’s disease. Other eligibility criteria apply. The purpose of this study is to test the safety, tolerability, and efficacy of an investigational oral drug, Sage-718 in PD-MCI. SAGE-718 is an investigational drug and is not approved by the US Food and Drug Administration (FDA) as safe and effective for any use. There is no guarantee that Sage-718 will be approved by the FDA. Learn more and find a study center near you.